Don C. Yoo Associate Professor of Diagnostic Imaging (Clinical)

Dr. Yoo is the Director of Nuclear Medicine at the Miriam Hospital and an Associate Professor of Diagnostic Imaging (clinical) at The Warren Alpert Medical School of Brown University. Dr. Yoo is Director of Medical Student Radiology Education and Co-director of the General Radiology Elective Biomed 629 and is involved in teaching radiology residents and medical students.

Dr. Yoo is a general radiologist with specialized training in nuclear medicine and positron emission tomography (PET). His main area of interest is in oncologic applications of PET. He is involved in researching the role of PET in radiofrequency ablation of lung cancers.

Dr. Yoo is heavily involved in the annual meeting of the American Roentgen Ray Society where he is a regular faculty member and also the Chair of the Education Compliance Subcommittee.  Dr. Yoo is involved with the American College of Radiology where he is a regular faculty member for the American College of Radiology - Dartmouth PET/CT Course and the annual American College of Radiology PET/CT Symposium.  Dr. Yoo is also the President of the New England Chapter of SNMMI.

Brown Affiliations

scholarly work

Yoo DC, Noto RB, Mazzaglia PJ.  Controversy over radioiodine ablation in thyroid cancer: who benefits?  Surgical Clinics of North America.  S2014 Jun;94(3):573-586

Yoo DC, Dupuy DE, Hillman SL, Fernando HC, Rilling WS, Shepard JA, Siegel BA. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome? American Journal of Roentgenology 2011 Aug;197(2):334-40.

Consultant and author of the Nuclear Medicine Section. Reference Levels and Achievable Doses in Medical and Dental Imaging: Recommendation for the United States. National Council on Radiation Protection & Measurements. NCRP Report No. 172. Bethesda MD Sept. 30, 2012

research overview

General oncologic applications with positron emission tomography (PET), especially using PET to evaluate the response to chemotherapy, radiation treatment, and image-guided techniques such as radiofrequency ablation.

research statement

Positron emission tomography (PET) utilizes positron-emitting radioactive tracer elements to produce images of physiologic function at a molecular level. The most commonly used radiopharmaceutical in PET is 18-F Fluorodeoxyglucose (18F-FDG). Many cancer cells are hypermetabolic and use glucose as a fuel. 18-F FDG is a glucose analog, which allows the detection of many cancers. PET is being used increasingly in oncology to diagnose, stage, and restage cancers after therapy. Rhode Island Hospital is participating in a national study using PET to predict long-term survival in patients with locally advanced lung cancer who undergo combined chemoradiotherapy. Rhode Island Hospital is a leading center for radiofrequency ablation of many tumors, and PET is often being used to evaluate the response of tumors to radiofrequency ablation. PET/CT is now available at Rhode Island Hospital. PET/CT combines physiologic and anatomic information in one study by fusing or overlaying the PET images and CT images together. PET/CT opens up new avenues for research at Rhode Island Hospital.

funded research

ACRIN 6668/ RTOG 0235
"Positron Emission Tomography Pre- and Post-Treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma"
Principle Investigator at Rhode Island Hospital
Funded by the American College of Radiology Imaging Network (ACRIN)
Funded for one year at $45,000
Dates of grant: 1/1/2006–12/31/2007